Murat Gökhan YERLİKAYA

Dr. Murat Gökhan YERLİKAYA

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Archives of Medical Science
Verified
Journal Article
Open access
TKTeoman Kilic
Teoman Kilic
AIAlfonso Ielasi
Alfonso Ielasi
VNVlasis Ninios
Vlasis Ninios
LKLevent Korkmaz
Levent Korkmaz
DPDemosthenes Panagiotakos
Demosthenes Panagiotakos
AAAli Rıza Akyüz
Ali Rıza Akyüz
Introduction: Limited data exist on long-term follow-up of severe aortic stenosis (SAS) patients who have undergone transcatheter aortic valve implantation (TAVI) with a new generation, balloon expandable Myval transcatheter heart valve (THV). Thus, we sought to investigate the performance and 2-year clinical outcome of the Myval THV system based on Valve Academic Research Consortium-3 (VARC-3) criteria.Material and methods: A multi-centre, registry-based, observational study was conducted, which included 207 consecutive degenerative SAS patients, from Turkey (n = 128), Italy (n = 58), and Greece (n = 21) (mean [standard deviation] 81 (7) years, 94 [45%] men; 73% NYHA III or IV; EuroSCORE II 5.2% [2.4%]); all patients underwent TAVI with Myval. Patients were followed up at 1 year and 2 years after implantation. Clinical and procedural outcomes were defined according to VARC-3 criteria.Results: Technical success was observed in 204 (99%), device success was observed in 189 (91%), early safety was observed in 161 (78%), and clinical efficacy was observed in 163 (79%) patients. The 30-day death rate was 7.7%; of these, 3.4% were due to cardiovascular reasons. All-cause and cardiovascular mortality rates were 9.7% and 4.3% at 1-year follow-up, and 17.4% and 9.7% at 2-year follow-up, respectively. Incidence of ≥ moderate paravalvular leak (PVL) at 30 days, 1 year and 2 years of follow-up were 3.4%, 4.3% and 4.8%. A total of 11.1% of patients required a permanent pacemaker implantation (PPI) at 30 days after implantation, while the cumulative rate of PPI at 2 years was 12.1%.Conclusions: In this cohort of patients with SAS, the Myval was found to be safe and effective in up to 2 years of follow-up.

30 March 2025 in Biomarkers in Medicine
Verified
Journal Article
Closed access
AYAbdullah Yıldırım
Abdullah Yıldırım
ÖGÖmer Genç
Ömer Genç
MEMert Evlice
Mert Evlice
AEAslan Erdoğan
Aslan Erdoğan
EPEmre Pacaci
Emre Pacaci
IKIbrahim Halil Kurt
Ibrahim Halil Kurt
This retrospective, multi-center study evaluates the relationships between novel liver function scoring systems - Albumin-Bilirubin (ALBI) score, EZ-ALBI, PALBI, and MELD-XI - and outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). Feature importance was assessed with SHAP-values via the XGBoost-algorithm. The ALBI score exhibited the strongest association with 30-day mortality after TAVI (AUC = 0.723, p < 0.001), outperforming other scores in this regard and consistently demonstrating predictive power across various subgroup populations. Higher 30-day mortality rates were observed in the higher tertiles of the ALBI score compared to the lower tertiles (log-rank p-value = 0.004). The ALBI-based nomogram (C-index = 0.81, 95% CI:0.73-0.86, p = 0 < 001) demonstrated superior predictive power for 30-day mortality post-TAVI compared to the STS (C-index = 0.71, 95% CI :0.64-0.77, p = 0 < 001). In addition, the nomogram showed a significant improvement in reclassification (69.3%, p < 0.001) and a stronger discrimination 15.2%, p < 0.001) compared to the STS. It integrates nine variables, first ALBI score (SHAP:1.165), including NYHA class (0.594), body mass index (0.510), glomerular filtration rate, creatinine, hemoglobin, gender, predilatation requirement, presence of chronic kidney disease, and providing a comprehensive risk assessment tool. This study exhibits the significance of liver dysfunction with AS patients and suggests incorporating liver function parameters in pre-operative risk assessments for better clinical outcomes in TAVI procedures.

1 March 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
AAAdnan Abaci
Adnan Abaci
MYMurat Gökhan YERLİKAYA
Murat Gökhan YERLİKAYA
TKTuğba Kapanşahin
Tuğba Kapanşahin
GSGöktuğ Savaş
Göktuğ Savaş
AAAli Rıza Akyüz
Ali Rıza Akyüz
HAHasan Ari
Hasan Ari
BACKGROUND: Isolated coronary artery ectasia (CAE) is a less common form of CAE. The clinical significance of isolated CAE has not been elucidated yet. We aimed to compare the patients with myocardial infarction (MI) due to isolated CAE with the patients without CAE. METHODS: We retrospectively included patients who underwent coronary angiography with a diagnosis of first MI caused by isolated CAE. We excluded patients with >20% stenosis in any vessel other than the lesion responsible for the MI. A second group of patients with MI without CAE was selected as the control group. The primary outcome was the composite of all-cause death and nonfatal recurrent MI occurring after index hospitalization. RESULTS: A total of 404 patients were included. Overall, 63.9% of MIs were ST-elevation MI. Almost all patients in the isolated CAE group had multivessel diffuse ectasia, with 71.3% classified as Markis I, and 26.7% as Markis II. Death or MI recurrence occurred in 54 (26.7%) patients in the isolated CAE group and 33 (16.3%) patients in the control group ( P =0.011). Death occurred in 8 (4.0%) patients in the isolated CAE group versus 6 (3.0%) patients in the control group; recurrent MI in 46 (22.8%) versus 27 (13.4%) patients, respectively. Stent thrombosis was more common in the CAE group compared with the control group (8.9% versus 1.5%; P <0.001). In multiple variable analysis, the presence of CAE was associated with death/recurrent MI (hazard ratio, 1.84 [95% CI, 1.11–3.05]; P =0.017), and recurrent MI (hazard ratio, 2.07 [95% CI, 1.08–3.96]; P =0.029). CONCLUSIONS: The patients with MI due to isolated CAE had a higher risk of recurrent MI and stent thrombosis compared with the patients without CAE. In this study, the rate of recurrent MI from the index infarct artery was also higher in the patients with CAE.

6 May 2026 in Lipids in Health and Disease
Verified
Journal Article
Open access
AÇAyşe Çolak
Ayşe Çolak
ZKZeynep Kumral
Zeynep Kumral
ÖÖÖnder Öztürk
Önder Öztürk
AKAyşegül ÜLGEN KUNAK
Ayşegül ÜLGEN KUNAK
AEALİ NİZAMİ ELMAS
ALİ NİZAMİ ELMAS
AEAsım Oktay Ergene
Asım Oktay Ergene
Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.

1 January 2025 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AÖAhmet Özderya
Ahmet Özderya
FGFATİH GÜLÇEBİ
FATİH GÜLÇEBİ
MYMurat Gökhan YERLİKAYA
Murat Gökhan YERLİKAYA
MMMehmet Ali Maz
Mehmet Ali Maz
SŞSinan Şahin
Sinan Şahin
MSMuhammet Raşit Sayın
Muhammet Raşit Sayın
OBJECTIVE: Cardiac implantable electronic devices are widely used today. Therefore, research is ongoing to provide better device implantation in technical terms. The aim of this study was to investigate the relationship between pre-procedural regional right ventricular strain and post-procedural endocardial R-wave amplitude in patients scheduled to receive an implantable cardiac defibrillator.

1 January 2025 in Sakarya Medical Journal
Verified
Journal Article
Open access
PDF file
AÖAhmet Özderya
Ahmet Özderya
EEEnder Emre
Ender Emre
EKEzgi Kalaycıoğlu
Ezgi Kalaycıoğlu
MYMurat Gökhan YERLİKAYA
Murat Gökhan YERLİKAYA
TGTayyar Gökdeniz
Tayyar Gökdeniz
MÇMustafa Çetin
Mustafa Çetin
Objective: To demonstrate the relationship of all-cause mortality in the long term and speckle-tracking echocardiography parameters in a cohort of diabetic hypertensive cases that had preserved left ventricle ejection fraction (LV-EF). Methods: The study included 141 diabetic hypertensive cases with preserved LV-EF were retrospectively analyzed. After applying exclusion criteria, 121 patients were included. Two groups were formed according to out-of-hospital mortality status. Laboratory and echocardiography data were analyzed. Results: The mean age of the 121 patients was 58.48.04 years, and the median follow-up duration was 10.08 years. Echocardiographic left atrial strain parameters, namely left atrium reservoir phase strain (35.7±8.7 vs 29.8±7.3, p-value: 0.047), left atrium conduit phase strain (LAScd%) (17.6±5.8 vs 13.3±4.1, p-value: 0.028), and left atrium reservoir phase peak strain (1.5±0.4 vs 1.22±0.3, p-value: 0.037), were worse in the mortality group. In right ventricular strain evaluation, four-chamber right ventricular strain (RV4CSL%) (26.1±5.4 vs. 20.8±6.2, p-value: 0.005) was also worse in the mortality group. Multivariate analysis revealed that the mean daytime systolic blood pressure (odds ratio [OR]: 1.769, p-value: 0.028), LAScd% (OR: 0.820, p-value: 0.015), RV4CSL% (OR: 0.078, p-value: 0.043) independently predicted mortality. Kaplan-Meier analysis showed that LAScd%≤15.3 and RV4CSL%≤24.8 were predictive of mortality (p-values: 0.023 and 0.016, respectively). Conclusion: Strain parameters, assessed via echocardiography, can be useful diagnostic and follow-up tools for determining prognosis and guiding early risk factor management in diabetic hypertensive patients, especially in comparison to traditional volumetric parameters.